FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560508979> ?p ?o ?g. }

• W2560508979 endingPage "151" @default.
• W2560508979 startingPage "145" @default.
• W2560508979 abstract "Background and Purpose— We conducted a randomized, open-label, phase 1/2a, dose-escalation study of intraventricular sustained-release nimodipine (EG-1962) to determine safety, tolerability, pharmacokinetics, and clinical effects in aneurysmal subarachnoid hemorrhage. Methods— Subjects with aneurysmal subarachnoid hemorrhage repaired by clipping or coiling were randomized to EG-1962 or enteral nimodipine. Subjects were World Federation of Neurological Surgeons grade 2 to 4 and had an external ventricular drain. Cohorts of 12 subjects received 100 to 1200 mg EG-1962 (9 per cohort) or enteral nimodipine (3 per cohort). The primary objective was to determine the maximum tolerated dose. Results— Fifty-four subjects in North America were randomized to EG-1962, and 18 subjects were randomized to enteral nimodipine. The maximum tolerated dose was 800 mg. One serious adverse event related to EG-1962 (400 mg) and 2 EG-1962 dose-limiting toxicities were without clinical sequelae. There was no EG-1962-related hypotension compared with 17% (3/18) with enteral nimodipine. Favorable outcome at 90 days on the extended Glasgow outcome scale occurred in 27/45 (60%, 95% confidence interval 46%–74%) EG-1962 subjects (5/9 with 100, 6/9 with 200, 7/9 with 400, 4/9 with 600, and 5/9 with 800 mg) and 5/18 (28%, 95% confidence interval 7%–48%, relative risk reduction of unfavorable outcome; 1.45, 95% confidence interval 1.04–2.03; P =0.027) enteral nimodipine subjects. EG-1962 reduced delayed cerebral ischemia (14/45 [31%] EG-1962 versus 11/18 [61%] enteral nimodipine) and rescue therapy (11/45 [24%] versus 10/18 [56%]). Conclusions— EG-1962 was safe and tolerable to 800 mg, and in this, aneurysmal subarachnoid hemorrhage population was associated with reduced delayed cerebral ischemia and rescue therapy. Overall, the rate of favorable clinical outcome was greater in the EG-1962-treated group. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01893190." @default.
• W2560508979 created "2016-12-16" @default.
• W2560508979 creator A5001908694 @default.
• W2560508979 creator A5016797598 @default.
• W2560508979 creator A5018029238 @default.
• W2560508979 creator A5028043510 @default.
• W2560508979 creator A5034715566 @default.
• W2560508979 creator A5049222047 @default.
• W2560508979 creator A5049720250 @default.
• W2560508979 creator A5058589297 @default.
• W2560508979 creator A5062595802 @default.
• W2560508979 creator A5090506665 @default.
• W2560508979 date "2017-01-01" @default.
• W2560508979 modified "2023-10-13" @default.
• W2560508979 title "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])" @default.
• W2560508979 cites W1565992055 @default.
• W2560508979 cites W1574261673 @default.
• W2560508979 cites W1966109927 @default.
• W2560508979 cites W1967281691 @default.
• W2560508979 cites W1969661146 @default.
• W2560508979 cites W1972491904 @default.
• W2560508979 cites W2000366267 @default.
• W2560508979 cites W2005687630 @default.
• W2560508979 cites W2015140911 @default.
• W2560508979 cites W2021044488 @default.
• W2560508979 cites W2041901504 @default.
• W2560508979 cites W2062079254 @default.
• W2560508979 cites W2070071679 @default.
• W2560508979 cites W2080504768 @default.
• W2560508979 cites W2090829979 @default.
• W2560508979 cites W2097128427 @default.
• W2560508979 cites W2111062482 @default.
• W2560508979 cites W2128973824 @default.
• W2560508979 cites W2133030798 @default.
• W2560508979 cites W2133891049 @default.
• W2560508979 cites W2136440984 @default.
• W2560508979 cites W2137299577 @default.
• W2560508979 cites W2141398018 @default.
• W2560508979 cites W2144456462 @default.
• W2560508979 cites W2157006832 @default.
• W2560508979 cites W2165758561 @default.
• W2560508979 cites W2169684975 @default.
• W2560508979 cites W2289349361 @default.
• W2560508979 cites W2296117242 @default.
• W2560508979 cites W2317146405 @default.
• W2560508979 cites W2571918371 @default.
• W2560508979 cites W2768689142 @default.
• W2560508979 doi "https://doi.org/10.1161/strokeaha.116.014250" @default.
• W2560508979 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5176000" @default.
• W2560508979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27932607" @default.
• W2560508979 hasPublicationYear "2017" @default.
• W2560508979 type Work @default.
• W2560508979 sameAs 2560508979 @default.
• W2560508979 citedByCount "48" @default.
• W2560508979 countsByYear W25605089792017 @default.
• W2560508979 countsByYear W25605089792018 @default.
• W2560508979 countsByYear W25605089792019 @default.
• W2560508979 countsByYear W25605089792020 @default.
• W2560508979 countsByYear W25605089792021 @default.
• W2560508979 countsByYear W25605089792022 @default.
• W2560508979 countsByYear W25605089792023 @default.
• W2560508979 crossrefType "journal-article" @default.
• W2560508979 hasAuthorship W2560508979A5001908694 @default.
• W2560508979 hasAuthorship W2560508979A5016797598 @default.
• W2560508979 hasAuthorship W2560508979A5018029238 @default.
• W2560508979 hasAuthorship W2560508979A5028043510 @default.
• W2560508979 hasAuthorship W2560508979A5034715566 @default.
• W2560508979 hasAuthorship W2560508979A5049222047 @default.
• W2560508979 hasAuthorship W2560508979A5049720250 @default.
• W2560508979 hasAuthorship W2560508979A5058589297 @default.
• W2560508979 hasAuthorship W2560508979A5062595802 @default.
• W2560508979 hasAuthorship W2560508979A5090506665 @default.
• W2560508979 hasBestOaLocation W25605089791 @default.
• W2560508979 hasConcept C126322002 @default.
• W2560508979 hasConcept C141071460 @default.
• W2560508979 hasConcept C168563851 @default.
• W2560508979 hasConcept C197934379 @default.
• W2560508979 hasConcept C2777294900 @default.
• W2560508979 hasConcept C2777736543 @default.
• W2560508979 hasConcept C2778375690 @default.
• W2560508979 hasConcept C42219234 @default.
• W2560508979 hasConcept C44249647 @default.
• W2560508979 hasConcept C519063684 @default.
• W2560508979 hasConcept C71924100 @default.
• W2560508979 hasConceptScore W2560508979C126322002 @default.
• W2560508979 hasConceptScore W2560508979C141071460 @default.
• W2560508979 hasConceptScore W2560508979C168563851 @default.
• W2560508979 hasConceptScore W2560508979C197934379 @default.
• W2560508979 hasConceptScore W2560508979C2777294900 @default.
• W2560508979 hasConceptScore W2560508979C2777736543 @default.
• W2560508979 hasConceptScore W2560508979C2778375690 @default.
• W2560508979 hasConceptScore W2560508979C42219234 @default.
• W2560508979 hasConceptScore W2560508979C44249647 @default.
• W2560508979 hasConceptScore W2560508979C519063684 @default.
• W2560508979 hasConceptScore W2560508979C71924100 @default.
• W2560508979 hasIssue "1" @default.
• W2560508979 hasLocation W25605089791 @default.
• W2560508979 hasLocation W25605089792 @default.

• next